U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C42H53NO15
Molecular Weight 811.8679
Optical Activity UNSPECIFIED
Defined Stereocenters 13 / 13
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ACLARUBICIN

SMILES

[H][C@@]1(CCC(=O)[C@H](C)O1)O[C@H]2[C@@H](O)C[C@]([H])(O[C@@H]3[C@H](C)O[C@]([H])(C[C@@H]3N(C)C)O[C@H]4C[C@](O)(CC)[C@H](C(=O)OC)C5=CC6=C(C(=O)C7=C(O)C=CC=C7C6=O)C(O)=C45)O[C@H]2C

InChI

InChIKey=USZYSDMBJDPRIF-SVEJIMAYSA-N
InChI=1S/C42H53NO15/c1-8-42(51)17-28(33-22(35(42)41(50)52-7)14-23-34(38(33)49)37(48)32-21(36(23)47)10-9-11-26(32)45)56-30-15-24(43(5)6)39(19(3)54-30)58-31-16-27(46)40(20(4)55-31)57-29-13-12-25(44)18(2)53-29/h9-11,14,18-20,24,27-31,35,39-40,45-46,49,51H,8,12-13,15-17H2,1-7H3/t18-,19-,20-,24-,27-,28-,29-,30-,31-,35-,39+,40+,42+/m0/s1

HIDE SMILES / InChI

Molecular Formula C42H53NO15
Molecular Weight 811.8679
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 13 / 13
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including: http://www.druginfosys.com/Drug.aspx?drugCode=29&drugName=Aclarubicin%20(HCl)&type=8

Aclarubicin (INN) or aclacinomycin A is an anthracycline drug is primarily indicated in conditions like Acute non-lymphoblastic leukemia, Breast cancer, Gastric cancer, Lymphoma, Ovarian coma, Small cell lung cancer, Thyroid cancer. Soil bacteria Streptomyces galilaeus can produce aclarubicin. Aclarubicin (HCl) is used in combination with different anticancerous drugs to obtain best therapeutic results and to reduce toxicity or side effects. Aclarubicin (HCl) is administered intravenously. Aclarubicin is antagonistic to other agents that inhibit topoisomerase II, such as etoposide, teniposide and amsacrine. This agent is less cardiotoxic than doxorubicin and daunorubicin.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
In vitro activities of free and liposomal drugs against Mycobacterium avium-M. intracellulare complex and M. tuberculosis.
1993 Dec
Comparison of anthracycline-induced death of human leukemia cells: programmed cell death versus necrosis.
2002 Dec
Expression of glutathione S-transferase P1-1 in differentiating K562: role of GATA-1.
2003 Nov 28
Mechanisms of induction of apoptosis by anthraquinone anticancer drugs aclarubicin and mitoxantrone in comparison with doxorubicin: relation to drug cytotoxicity and caspase-3 activation.
2005 Dec
Aclarubicin-induced apoptosis and necrosis in cells derived from human solid tumours.
2010 Jul 19
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
2011 Jul 14
Patents

Sample Use Guides

25 to 100 mg/sq.meter. Maintenance, Every 3-4 Week
Route of Administration: Intravenous
In Vitro Use Guide
aclarubicin (ACR) blocked the human lymphocytes progression at G1 period at the concentrations of 100 and 200 ng/ml, but the number of dead cells was not increased.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:16:53 UTC 2023
Edited
by admin
on Fri Dec 15 15:16:53 UTC 2023
Record UNII
74KXF8I502
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ACLARUBICIN
INN   MART.   USAN   WHO-DD  
USAN   INN  
Official Name English
ACLARUBICIN [JAN]
Common Name English
ACLACINOMYCIN A
MI  
Common Name English
Aclarubicin [WHO-DD]
Common Name English
ACLACINOMYCIN A [MI]
Common Name English
ACLARUBICIN [USAN]
Common Name English
ACLARUBICIN [MART.]
Common Name English
NSC-208734
Code English
aclarubicin [INN]
Common Name English
Classification Tree Code System Code
WHO-VATC QL01DB04
Created by admin on Fri Dec 15 15:16:53 UTC 2023 , Edited by admin on Fri Dec 15 15:16:53 UTC 2023
WHO-ATC L01DB04
Created by admin on Fri Dec 15 15:16:53 UTC 2023 , Edited by admin on Fri Dec 15 15:16:53 UTC 2023
NCI_THESAURUS C987
Created by admin on Fri Dec 15 15:16:53 UTC 2023 , Edited by admin on Fri Dec 15 15:16:53 UTC 2023
Code System Code Type Description
CAS
57576-44-0
Created by admin on Fri Dec 15 15:16:53 UTC 2023 , Edited by admin on Fri Dec 15 15:16:53 UTC 2023
PRIMARY
PUBCHEM
451415
Created by admin on Fri Dec 15 15:16:53 UTC 2023 , Edited by admin on Fri Dec 15 15:16:53 UTC 2023
PRIMARY
CHEBI
77980
Created by admin on Fri Dec 15 15:16:53 UTC 2023 , Edited by admin on Fri Dec 15 15:16:53 UTC 2023
PRIMARY
ChEMBL
CHEMBL502620
Created by admin on Fri Dec 15 15:16:53 UTC 2023 , Edited by admin on Fri Dec 15 15:16:53 UTC 2023
PRIMARY
MESH
D015250
Created by admin on Fri Dec 15 15:16:53 UTC 2023 , Edited by admin on Fri Dec 15 15:16:53 UTC 2023
PRIMARY
ECHA (EC/EINECS)
260-824-3
Created by admin on Fri Dec 15 15:16:53 UTC 2023 , Edited by admin on Fri Dec 15 15:16:53 UTC 2023
PRIMARY
NCI_THESAURUS
C202
Created by admin on Fri Dec 15 15:16:53 UTC 2023 , Edited by admin on Fri Dec 15 15:16:53 UTC 2023
PRIMARY
SMS_ID
100000084625
Created by admin on Fri Dec 15 15:16:53 UTC 2023 , Edited by admin on Fri Dec 15 15:16:53 UTC 2023
PRIMARY
RXCUI
239
Created by admin on Fri Dec 15 15:16:53 UTC 2023 , Edited by admin on Fri Dec 15 15:16:53 UTC 2023
PRIMARY RxNorm
DRUG CENTRAL
80
Created by admin on Fri Dec 15 15:16:53 UTC 2023 , Edited by admin on Fri Dec 15 15:16:53 UTC 2023
PRIMARY
FDA UNII
74KXF8I502
Created by admin on Fri Dec 15 15:16:53 UTC 2023 , Edited by admin on Fri Dec 15 15:16:53 UTC 2023
PRIMARY
INN
4945
Created by admin on Fri Dec 15 15:16:53 UTC 2023 , Edited by admin on Fri Dec 15 15:16:53 UTC 2023
PRIMARY
WIKIPEDIA
ACLARUBICIN
Created by admin on Fri Dec 15 15:16:53 UTC 2023 , Edited by admin on Fri Dec 15 15:16:53 UTC 2023
PRIMARY
CHEBI
74619
Created by admin on Fri Dec 15 15:16:53 UTC 2023 , Edited by admin on Fri Dec 15 15:16:53 UTC 2023
PRIMARY
EVMPD
SUB05243MIG
Created by admin on Fri Dec 15 15:16:53 UTC 2023 , Edited by admin on Fri Dec 15 15:16:53 UTC 2023
PRIMARY
EPA CompTox
DTXSID1022554
Created by admin on Fri Dec 15 15:16:53 UTC 2023 , Edited by admin on Fri Dec 15 15:16:53 UTC 2023
PRIMARY
MERCK INDEX
m1374
Created by admin on Fri Dec 15 15:16:53 UTC 2023 , Edited by admin on Fri Dec 15 15:16:53 UTC 2023
PRIMARY Merck Index
DRUG BANK
DB11617
Created by admin on Fri Dec 15 15:16:53 UTC 2023 , Edited by admin on Fri Dec 15 15:16:53 UTC 2023
PRIMARY
NSC
208734
Created by admin on Fri Dec 15 15:16:53 UTC 2023 , Edited by admin on Fri Dec 15 15:16:53 UTC 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY